½Å»ý¾Æ °æ·Ã¿¡¼­ Ç×°æ·ÃÁ¦ÀÇ È¿°ú ¹× ¿¹ÈÄ¿¡ ¹ÌÄ¡´Â ¿µÇâ
The Impact of Anticonvulsants on Neurologic Outcomes in Neonatal Seizures

´ëÇÑÁÖ»êÀÇÇÐȸÀâÁö 2014³â 25±Ç 2È£ p.83 ~ p.90

ÇÑÁöÀ±(Han Ji-Yoon) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌÁøÈñ(Lee Jin-Hee) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¹Ú¼±¿µ(Park Sun-Young) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¹®Ã»ÁØ(Moon Chung-Joon) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
À±¿µ¾Æ(Youn Young-Ah) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¼ºÀΰæ(Sung In-Kyung) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌÀα¸(Lee In-Goo) - °¡Å縯´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

Abstract

¸ñÀû : ½Å»ý¾Æ °æ·ÃÀº »ç¸Á·üÀÌ ³ô°í, ÈÄÀ¯ÁõÀ¸·Î ½Å°æ¹ß´Þ Àå¾Ö, ³úÀüÁõ µîÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Â ÁúȯÀÌÁö¸¸, »ç¿ëÇÒ ¼ö ÀÖ´Â Ç×°æ·ÃÁ¦°¡ Á¦ÇÑÀûÀ̸ç À̵éÀÌ ¿¹ÈÄ¿¡ ¾î¶² ¿µÇâÀ» ÁÖ´ÂÁö ¹àÇôÁ® ÀÖÁö ¾Ê´Ù. ÀÌ¿¡ ÀúÀÚµéÀº ½Å»ý¾Æ °æ·Ã ȯ¾ÆµéÀÇ ¿¹Èĸ¦ Åõ¿©ÇÑ Ç×°æ·ÃÁ¦ÀÇ °³¼ö¿Í ³úÆÄ°Ë»ç¸¦ ÅëÇØ ¾Ë¾Æ º¸¾Ò´Ù.

¹æ¹ý : 2012³â 1¿ùºÎÅÍ 2012³â 6¿ù±îÁö ¼­¿ï¼º¸ðº´¿ø ½Å»ý¾Æ ÁßȯÀڽǿ¡ ÀÔ¿øÇÑ È¯¾Æµé Áß °æ·ÃÀ» ÀÏÀ¸Å² ÀçÅ ¿¬·É 44ÁÖ ¹Ì¸¸ÀÇ ½Å»ý¾Æ 37¸í(³²ÀÚ 18¸í, ¿©ÀÚ 19¸í, ¸¸»è¾Æ 13¸í, ¹Ì¼÷¾Æ 24¸í)À» ´ë»óÀ¸·Î ÈÄÇâÀû Àǹ«±â·Ï ºÐ¼®À» ÇÏ¿´´Ù.

°á°ú : ´ë»ó ȯ¾Æ 37¸íÀÇ Æò±Õ ÀçÅ ¿¬·ÉÀº 32.5¡¾1.9ÁÖ, Æò±Õ Ãâ»ý üÁßÀº 2,010¡¾82 g À̾ú´Ù. °æ·ÃÀº ȯ¾ÆµéÀÇ 65%°¡ Ãâ»ý ÈÄ 7ÀÏ ³»¿¡ ¹ß»ýÇÏ¿´´Âµ¥, ƯÈ÷ 48½Ã°£¿¡¼­ 7ÀÏ À̳»°¡ °¡Àå ¸¹¾Ò°í(38%), ºñÀüÇüÀû °æ·Ã(51%)ÀÌ °¡Àå ÈçÇÑ ÇüÅ À̾ú´Ù. ´ë»ó ȯ¾ÆµéÀÇ 94% (35¸í)°¡ ³ú¿µ»ó °Ë»ç¿¡¼­ ÀÌ»ó ¼Ò°ßÀ» º¸¿´´Âµ¥, Àú»ê¼Ò¼º ÇãÇ÷¼º ³úº´ÁõÀÌ 62% (23¸í)·Î °¡Àå ¸¹¾Ò´Ù. ³úÆÄ°Ë»ç¿¡¼­´Â 62%°¡ ÀÌ»ó ¼Ò°ßÀ» º¸¿´´Âµ¥, Áߵ ÀÌ»óÀÌ 54% (20¸í), ±×¸®°í ÁßÁõ ÀÌ»óÀÌ 8% (3¸í) À̾ú°í, 6°³¿ù ÈıîÁö ³úÆÄ¿¡ ÀÌ»óÀÌ ÀÖ´Â °æ¿ì´Â 19% (7¸í)À̾ú´Ù. ´ë»ó ȯ¾Æ 37¸í Áß¿¡¼­ 57% (21¸í)´Â levetiracetam ¸¸À¸·Îµµ °æ·ÃÀÌ Á¶Àý µÇ¾úÁö¸¸, 19% (7¸í)´Â ¼¼°¡Áö ÀÌ»óÀÇ Ç×°æ·ÃÁ¦¸¦ º´¿ë Åõ¿©ÇÏ¿© °æ·ÃÀ» Á¶Àý ÇÏ¿´´Ù. Ä¡·á 6°³¿ù ÈÄ ÇѰ¡Áö Ç×°æ·ÃÁ¦·Î °æ·ÃÀÌ Á¶ÀýµÇ¾ú´ø ȯ¾Æµé¿¡¼­´Â ³úÀüÁõÀÌ 6% (2¸í), ¹ß´Þ Áö¿¬ÀÌ 19% (4¸í)¿¡¼­ ¹ß»ýÇÑ ¹Ý¸é ¼¼°¡Áö ÀÌ»óÀÇ Ç×°æ·ÃÁ¦¸¦ »ç¿ëÇÑ È¯¾Æ¿¡¼­´Â ³úÀüÁõÀÌ 29% (2¸í), ¹ß´Þ Áö¿¬ÀÌ 86% (6¸í)¿¡¼­ ¹ß»ýÇÏ¿´´Ù. ±×¸®°í Á¤»ó ³úÆÄ ¼Ò°ßÀ» º¸¿´´ø ȯ¾ÆµéÀÇ 86% (12¸í)°¡ 6°³¿ù ÈÄ Á¤»ó ¹ß´ÞÀ» º¸À̰í ÀÖ¾úÀ¸³ª, ÁßÁõÀÇ ³úÆÄÀÌ»ó ¼Ò°ßÀ» º¸¿´´ø ȯ¾Æµé(3¸í)Áß¿¡ Á¤»ó ¹ß´ÞÀ» º¸ÀÌ´Â °æ¿ì´Â ¾ø¾ú´Ù.

°á·Ð : ½Å»ý¾Æ °æ·Ã Ãʱ⿡ °æ·ÃÀÌ Á¶ÀýµÇÁö ¾Ê¾Æ »ç¿ëÇÏ´Â Ç×°æ·ÃÁ¦ÀÇ °³¼ö°¡ Áõ°¡ÇÒ¼ö·Ï, ±×¸®°í ³úÆÄ°Ë»ç¿¡¼­ ÁßÁõÀÇ ÀÌ»ó ¼Ò°ßÀ» º¸ÀÌ´Â °æ¿ì ½Å°æÇÐÀû ¿¹Èİ¡ ÁÁÁö ¾Ê¾Ò´Ù.
Purpose : Although neonatal seizures can cause epilepsy, neurodevelopmental disability, and mortality with high frequency, the use of anti-epileptic drug is limited and the side effect of the drug is unidentified. Thus, authors investigated the prognosis of the neonatal seizures related with anti-epileptic drugs and electroencephalography.

Methods : Retrospective medical records of 37 infants with neonatal seizures under 44 weeks of gestational age who were hospitalized at neonatal intensive care unit in Seoul St. Mary¡¯ Hospital from January to June 2012 were analyzed.

Result : The mean gestational age was 32.5¡¾1.9 weeks and the mean birth weight was 2,010¡¾82 g. Seizures occurred in 65% in infants within 7 days of birth and subtle seizures were most common type. Hypoxic ischemic encephalopathy was the most common cause of seizures and 62% showed abnormal electrographic findings. Among 37 of patients, seizures of 57% were able to be controlled by levetiracetam, but 19% were controlled by co-administration of more than three anti-epileptic drugs. After 6 months of treatment, epilepsy was diagnosed in 6% and developmental delay occurred in 19% among patients controlled by one anti-epileptic drug. Epilepsy and developmental delay occurred in 29% and 86%, respectively, among patients with more than three anti-epileptic drugs. In addition 86% of patients with normal electroencephalographic findings show normal development, but 3 patients with severe abnormalities showed abnormal development.

Conclusion : Neurologic outcome was not good when the number of anti-epileptic drugs were added due to uncontrolled seizures, and the result of electroencephalography showed severe abnormalities.

Ű¿öµå

½Å»ý¾Æ, °æ·Ã
Levetiracetam, Newborn, Seizures, Levetiracetam
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå